Rheumatism

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
星期三, 五月 8, 2024
PFS, Myopathy, Patient, Research and development, Investment, Colorectal cancer, Progression-free survival, Research, Immunoglobulin M, CD38, Bevacizumab, Trial of the century, Lupus, Administration, Rheumatoid arthritis, IGM, Myositis, SLE, Clinical trial, FOLFIRI, Rheumatism, GAAP, G&A

MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended March 31, 2024 and provided an update on recent developments.

Key Points: 
  • MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended March 31, 2024 and provided an update on recent developments.
  • Collaboration Revenue: For the first quarter of 2024 and 2023, collaboration revenues were $0.5 million in each quarter.
  • Research and Development (R&D) Expenses: For the first quarter of 2024, R&D expenses were $43.8 million, compared to $50.9 million for the first quarter of 2023.
  • General and Administrative (G&A) Expenses: For the first quarter of 2024, G&A expenses were $10.5 million, compared to $13.0 million for the first quarter of 2023.

Two Canadian teams awarded new funding to study mental illness in youth with rheumatic diseases

Retrieved on: 
星期四, 四月 11, 2024
University, Rheumatology, Arthritis, Partnership, Research, Mental health, Brain, Rheumatism, Child, Lupus, Juvenile idiopathic arthritis, Prevalence, Nursing

This year’s awardees are Roberta Berard, from the London Health Science Centre and Mark Ferro, of the University of Waterloo.

Key Points: 
  • This year’s awardees are Roberta Berard, from the London Health Science Centre and Mark Ferro, of the University of Waterloo.
  • Both teams are advancing efforts to better prevent, diagnose, and treat mental illnesses in children and young adults with rheumatic diseases such as juvenile idiopathic arthritis and lupus.
  • These conditions affect approximately 24,000 children and youth across Canada, impacting their daily lives and overall well-being.
  • "Our partnership reaffirms our dedication to supporting groundbreaking research that has the capacity to profoundly improve the lives of Canadian youth navigating mental health challenges."

FDA Grants Orphan Drug Designation for the Treatment of Scleroderma

Retrieved on: 
星期四, 四月 11, 2024
Collagen, Pain, FDA, Mortality, University, Patient, RFU, Systemic scleroderma, Risk, Skin, Food, Death, Helix, BLR, Research, Disease, Scleroderma, Rheumatology, Fatigue, Fibrosis, Public, Rheumatism, Multimedia, Myofibroblast, Pharmaceutical industry

NORTH CHICAGO, Ill., April 11, 2024 /PRNewswire/ -- BLR Bio, an emerging biotechnology company in Rosalind Franklin University's Helix 51 biomedical incubator , announced that the U.S. Food and Drug Administration (FDA) granted an Orphan Drug Designation for its investigational therapy BLR-200 for the treatment of systemic sclerosis (SSc), also known as scleroderma.

Key Points: 
  • NORTH CHICAGO, Ill., April 11, 2024 /PRNewswire/ -- BLR Bio, an emerging biotechnology company in Rosalind Franklin University's Helix 51 biomedical incubator , announced that the U.S. Food and Drug Administration (FDA) granted an Orphan Drug Designation for its investigational therapy BLR-200 for the treatment of systemic sclerosis (SSc), also known as scleroderma.
  • Orphan Drug Designation is granted by the FDA to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the U.S.
  • "The FDA's granting of Orphan Drug Designation to BLR-200 highlights the urgent need for new and innovative therapeutic options for patients afflicted with the disease."
  • Dr. Ronald Kaplan, RFU executive vice president for research, said the orphan designation represents an important milestone in the development of BLR Bio's drug candidate.

Remission Medical Partners with Sterling Urgent Care to Expand Access to Rheumatology Services

Retrieved on: 
星期二, 四月 9, 2024
Diagnosis, Arthralgia, Patient, Medicine, Cardiology, Partnership, Rheumatism, PRO, Quality of life, Sterling, LLM, Arthritis, CDC, Region, Work, Human, Hospital

RICHMOND, Va., April 9, 2024 /PRNewswire/ -- Remission Medical announced a partnership with clinical innovator Sterling Urgent Care, to make access to Rheumatology treatment far more convenient across four states: Idaho, Utah, Wyoming and Montana.

Key Points: 
  • Remission Medical is a national virtual clinic offering diagnosis and longitudinal care in Rheumatology, powered by video visits and a technology platform focused on escalation avoidance.
  • According to Sterling Urgent Care spokesperson Dan Kenning, with 21 locations across four states, Sterling goes beyond typical urgent care.
  • They offer advanced primary care in specialties like cardiology, pulmonology, and now rheumatology, prioritizing swift and accurate diagnosis and treatment.
  • Sterling also leads in affordable healthcare with unique membership programs for individuals and businesses, aiming to provide quality care to those without access.

RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome

Retrieved on: 
星期三, 四月 3, 2024
Rheumatoid arthritis, Autoimmunity, Lupus, Risk, Rheumatism, Patient, PSS, SLE, Diabetic nephropathy, Myasthenia gravis, IND, Mouth, Investigational New Drug, Cytokine, B-cell activating factor, Iga, FDA, FTD

The FDA grants FTD to accelerate the development and review of new drugs that have the potential to treat life-threatening conditions and address unmet medical needs.

Key Points: 
  • The FDA grants FTD to accelerate the development and review of new drugs that have the potential to treat life-threatening conditions and address unmet medical needs.
  • Telitacicept prevents abnormal differentiation and maturation of B-cells through a two-pronged approach, thereby treating various autoimmune diseases mediated by B-cells.
  • In December 2023, Telitacicept was granted Investigational New Drug (IND) by the FDA for the treatment of active pSS in adults.
  • Dr. Jianmin Fang, CEO of RemeGen, commented, "As the first fusion protein drug of its kind independently developed by RemeGen, we are delighted the FDA has recognized Telitacicept for fast track designation.

Remission Medical Partners with Sentara Health to Expand Access to Rheumatology Care

Retrieved on: 
星期三, 三月 20, 2024
Arthralgia, Diagnosis, Health, Rheumatoid arthritis, Medicine, Telehealth, Partnership, Part, Rheumatism, Patient, Triage, Joint, MD, Quality of life, Arthritis, Medical specialty, CDC, Work, Pharmaceutical industry

RICHMOND, Va. , March 20, 2024 /PRNewswire/ --Remission Medical announced a partnership with Sentara Health to increase access to Rheumatology care for adult patients.For 130 years, Sentara has pursued its mission - "we improve health every day."  Part of improving health is ensuring swift access to specialists, with maximum convenience including video visits.According to the CDC, one in four US adults have a rheumatic condition, especially arthritis, which is characterized by joint pain and stiffness.  Rheumatic disease can affect quality of life, both at home and work, and can be hard to diagnose, given there are some 150 disease varieties."The medical literature shows that the time to diagnosis and treatment matters for certain conditions in rheumatology such as rheumatoid arthritis," says Steven Pearman, MD, Vice President and Chief Medical Officer of Medical Specialties from Sentara Health. "Starting treatment with the right therapy can avoid the damage to joints that comes with these conditions. In addition, access to Rheumatology is limited by increasing demand and a dwindling supply of specialists. Telehealth is well-suited for rapid triage and timely access to care."

Key Points: 
  • RICHMOND, Va. , March 20, 2024 /PRNewswire/ --Remission Medical announced a partnership with Sentara Health to increase access to Rheumatology care for adult patients.
  •  Part of improving health is ensuring swift access to specialists, with maximum convenience including video visits.
  • "The medical literature shows that the time to diagnosis and treatment matters for certain conditions in rheumatology such as rheumatoid arthritis," says Steven Pearman, MD, Vice President and Chief Medical Officer of Medical Specialties from Sentara Health.
  • "We're a Virginia company," said Blake Wehman, Founder & CEO of Remission Medical, "and we've witnessed how Sentara innovates in patient access, digital health and value-based care.

Withdrawn application: Orencia, 19/02/2024

Retrieved on: 
星期三, 四月 3, 2024
CD86, Graft-versus-host disease, Gene, Methotrexate, Psoriasis, Letter, Cell, Bone marrow, Risk, Inflammation, Patient, Ageing, Psoriatic arthritis, HSCT, Allele, Joint, Protein, HLA, European Medicines Agency, Arthritis, Syringe, Rheumatism, Agency, Clinical trial, Skin, CD80, Cancer, Immune system, Blood, Calcineurin, Medicine, Vaccine

Withdrawn application: Orencia, 19/02/2024

Key Points: 


Withdrawn application: Orencia, 19/02/2024

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis

Retrieved on: 
星期二, 十一月 14, 2023
Regeneron Pharmaceuticals, Osteoporosis, Research, Albany Medical College, UCB, Osteoarthritis, Disease, Tissue, Clinical trial, Teaching hospital, Internal medicine, Patient, Bristol Myers Squibb, Reiko True, AbbVie, Arthritis, Joint, Rheumatology, Health, Abstract, North Shore University Hospital, Pain, Janssen, APG system, Rheumatism, Confusion, GSK plc, HIV disease progression rates, Inflammation, Amgen, Cryptocurrency, Pharmaceutical industry, Pfizer, Rheumatoid arthritis, Takeda, Genentech

is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis.

Key Points: 
  • is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis.
  • The company has now enrolled about 33% of the 210 patients it is recruiting for a Phase II, Double-Blind, Placebo-Controlled, Randomized study, examining Natrunix in combination with methotrexate for the treatment of Rheumatoid Arthritis.
  • I am excited to be part of a clinical trial program studying a novel approach to RA.”
    Dr. Kivitz has had a prodigious medical career treating arthritis and rheumatic diseases.
  • Dr. Kivitz has authored over 500 research articles, abstracts, and clinical studies relating to osteoarthritis, osteoporosis and rheumatoid arthritis and has lectured on his findings around the world.

Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok

Retrieved on: 
星期一, 十二月 4, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Rheumatism, IL-7, Congress, WAC, Inflammation, World Allergy Organization, Abstract, Biology, Research fellow, TSLP, Vaccine, Forestry

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced two abstracts were accepted and presented at World Allergy Congress (WAC), held December 1 – 3, 2023 in Bangkok, Thailand.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced two abstracts were accepted and presented at World Allergy Congress (WAC), held December 1 – 3, 2023 in Bangkok, Thailand.
  • “Introducing Zura Bio’s ZB-168 and ZB-880 at World Allergy Congress is an opportunity to share the unique science behind these assets.
  • ZB-168 uniquely inhibits both IL-7 and TSLP, while ZB-880 prevents IL-33 mediated-activation of ST2-dependent and independent inflammation.
  • “We believe these could have applicability in the dermatological, rheumatological, gastrointestinal and respiratory spaces, and we are very excited about taking these development programs forward.”

HSS Presents New Reproductive Health Research at the ACR Convergence 2023

Retrieved on: 
星期二, 十一月 14, 2023
Knowledge, Woman, Cervical cancer, Contraindication, Patient, Rheumatoid arthritis, Documentation, SLE, Infertility, Diagnosis, Rheumatology, Rheumatism, Fertility, Prevalence, Menopause, Vaccination, Cryopreservation, Flare, DSM-IV codes, Birth, Connective tissue, Hospital for Special Surgery, Doctor of Public Health, Female, Fetus, Smoking, Senior counsel, RD, SAN, Menstrual cycle, Weill Cornell Medicine, Immunosuppression, Risk, History, Hysterectomy, Inflammatory arthritis, Lupus, HSS, PAP, Fertilisation, OOC, Research, Human papillomavirus infection, Ageing, Scleroderma, Systemic scleroderma, Vaccine, American College, American College of Rheumatology, COVID-19, Fertility preservation, MPH, ACR, HPV, Hospital, Birth control, Nursing, Food delivery, MD

Additional research is planned to assess whether demographics, lifestyle and medical conditions may influence this potential association.

Key Points: 
  • Additional research is planned to assess whether demographics, lifestyle and medical conditions may influence this potential association.
  • This study surveyed women of reproductive age with systemic rheumatic disease about their use of contraceptives.
  • Data were collected on 249 women with reproductive capacity, including 147 with inflammatory arthritis and 102 with lupus-like disorders.
  • This study used data from the electronic health record of patients diagnosed with a rheumatic disease in adolescence, seen at HSS, to look at factors associated with HPV vaccination.